Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Risk factors for failure to complete step-up-dosing of bispecific antibody therapy for B-cell lymphomas

View Full Paper
Ask AI
Bookmark
Share

Authors

JCJordan S. Carter

Discussion

Loading...

Member takes

Overview

Retrospective analysis highlights risks such as elevated LDH influencing treatment completion and survival in B-cell lymphoma patients.

Key Points

  • Elevated LDH significantly increased the risk of not completing step-up dosing of bispecific antibody therapy.
  • Generalized linear model analysis showed a clear association between treatment outcomes and factors such as advanced disease stage.
  • Median follow-up for patients was 8.7 months, with notable differences in overall response and progression-free survival.
  • Identified risk factors for treatment failure may indicate the need for alternative strategies or pre-treatment bridging approaches.

Cite This Study

Jordan S. Carter (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e582https://doi.org/10.1182/blood-2025-5522
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcomes of patients (Pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) progressing after CD3xCD20 bispecific antibody (BsAb) therapy: A new unmet need2025
  2. 2Outcomes following disease progression after epcoritamab or glofitamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study2025 · 1 citations
  3. 3Toxicity, efficacy, and clinical management of bispecific antibodies in routine clinical practice: A real-world geltamo study in B-cell lymphoma2025
  4. 4Feasibility and safety of accelerated glofitamab step-up in rapidly progressive relapsed/refractory diffuse large B-cell lymphoma: A real-world single center experience2025
  5. 5Real world outcomes of sequencing bispecific antibodies (BsAb) in patients with relapsed / refractory follicular lymphoma (R/R FL): A multi-center cohort study from cubic consortium2025